 |
|
What Are the Risks of Serious Infections and Malignancies for Patients Treated With Anti-Tumor Necrosis Factor Antibodies?
Rosamaria Corona, DSc, MD;
Michael Bigby, MD
Arch Dermatol. 2007;143(3):405-406.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Commentary on: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials
Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V.
JAMA. 2006;295:2275-2285
Question: In patients with rheumatoid arthritis treated with infliximab or adalimumab, what is the risk of serious infection or malignancy compared with patients with rheumatoid arthritis who do not receive either anti–tumor necrosis factor (TNF) antibody?
Data Sources: The authors performed a meta-analysis to derive estimates of sparse harmful events occurring in randomized trials of infliximab or adalimumab. A systematic literature search of EMBASE, MEDLINE, Cochrane Library, and electronic abstract databases of the annual scientific meetings of both the European League Against Rheumatism and the American College of Rheumatology was conducted through December 2005. This search was complemented with interviews . . . [Full Text of this Article] Comment
AUTHOR INFORMATION
Istituto Dermopatico dell’Immacolata, Rome, Italy (Dr Corona), and Department of Dermatology, Harvard Medical School, and Beth Israel Deaconess Medical Center, Boston, Mass (Dr Bigby)
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis
McGonagle et al.
Rheumatology (Oxford) 2008;47:865-867.
ABSTRACT
| FULL TEXT
|
